Here is the update on the Prostagene test.
The ProstaGene
Prognostic Test, for example, cannot move forward until the Company hires bioinformatician Dr.
Andrew Kossenkov to generate data for the Company's 51O(k) application to the FDA and for the
substantiated. This recommendation has not been followed. Of course, this issue is of particular
concern because misleading statements made to the public are both unlawful and harmful to the
Company and its shareholders.
13 See June 4, 2019 Interview with Proactive Investors, entitled "CytoDyn shows value of company
lies in their research and technology."
Market Data 
Markets 
AI
